This case report describes a woman in her 60s flesh-colored papules that were localized to the central face and a lobular downgrowth of cells with clear, expanded, faintly glassy cytoplasm.
P erioperative use of biologics has been a highly debated topic. Concerns regarding wound healing and infection risk have driven many physicians to hold biologic therapies perioperatively. Despite an increase in recent research on this topic, guidelines have not been updated in over a decade. Furthermore, current guidelines have conflicting evidence regarding when biologics should be held before major surgical procedures. The British Association of Dermatologists recommends withholding biologics for 4 half-lives before a surgery; however, this, like many of the other associations, has not been updated to reflect more recent research. 1 With the increasing number and use of biologic therapies, it is important to establish management protocols for the perioperative use of these agents in patients undergoing surgical procedures. Research suggests that biologics before low-risk surgical procedures incur no increased risk to patients; thus, certain medications may be safely continued preoperatively. [2][3][4] Table 1 summarizes currently published research on this topic. In this article, we aim to discuss the recent evidence on the safety of perioperative biologic therapy before higher risk surgeries. We also aim to advocate for an update in the current management guidelines.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.